As a consultant and co-founder of Product Quality Alliance, Mark Feild, holds a Ph.D. from North Carolina State University in Biochemistry and has over 30 years of experience in analytical development, product characterization, product stability, and validation studies throughout the entire product lifecycle. Involvement with products include monoclonal antibodies, fusion proteins, novel biotherapeutics, biosimilars, vaccines, gene therapy products (virus-like particles), and cell therapy-type products. An accomplished department director responsible for leading the development, commercialization, and analytical control strategies for numerous bio-pharmaceutical products. Proven leadership, skilled in setting the strategic analytical goals for Quality Control, Analytical Development, and Research.In 2005, Mark co-founded WindRose Analytica, Inc., a contract development and testing laboratory providing services for analytical program lifecycle development, performing method development, qualification, validation, stability studies and QC testing. Windrose was successfully acquired by Althea Technologies, Inc. in 2009, where Mark continued working through 2014 before co-founding Product Quality Alliance, LLC.Product Quality Alliance is a company that provides consulting services for assisting in devising analytical development strategies, QC testing, Stability Studies, and coordinating with GMP manufacturing of pharmaceutical and biopharmaceutical products, devices, and gene therapy products. We have extensive CMC experience in product development from early stage through commercialization and beyond. Our experience includes supporting companies that are challenged with managing the “Cost of Quality”, helping to reduce failures, defects, and rework.
Listed skills include Validation, Biopharmaceuticals, Technology Transfer, Biotechnology, and 26 others.